Discovery R&D Title The Global Structure of Breast Cancer R&D Sub title Author BioSeeker Publication date September 2003 ISBN - n/a - Pages 302 Price pdf £1220   |   print n/a Summary The Global Structure of Breast Cancer R&D has information about new innovative cancer therapies such as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones and apoptotic drugs are analyzed in more than 100 extensive tables and graphs. This report will give you easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mechanism. The graphs provide all the relations of these factors as well as the general and specific trends in the current breast cancer pipeline. Included in this 300+ page report: Information on more that 180 companies active in breast cancer R&D Information on more that 380 industry related breast cancer projects Data from 198 clinical trials Information on more than 140 preclinical projects 105 graphs illustrating the relations between types of therapy, effects and mechanisms Advanced analysis of general and specific trends in the pipeline The data has been structured as follows: Therapy Given - such as Antisense, Biological drug, Cell therapy, Monoclonal antibody, or Small molecular drug etc. Therapeutic Effect - such as Antiangiogenesis, Immunotherapy, Apoptosis, Cytotoxic, Growth Inhibition, or Vascular Targeting etc. Mechanism of Action - such as Estrogen modulation, Cell-cycle inhibition, targeting of Bcl-2 or p53, VEGF or EGF Antagonist, or TumorAntigen etc. Companies analysed in this report include: Aastrom Biosciences Abbott Laboratories, Acceptys, ACCESS Oncology, Adherex Technologies, Agouron Pharmaceuticals, Alfacell, Allergan Specialty Therapeutics, AllosTherapeutics, AlphaVax, AltaRex,ALZA, AMDL, AmericanPharmPartners, AngstromPharmaceuticals, AntigenicsAnti soma, Aphton, ARIUS Research, Arriva, AstraZeneca, Aurazyme Pharmaceuticals, Austrian Nordic, AVAX Technologies, Aventis, Banyu Pharmaceutical, Bavarian Nordic, Baxter, Bayer, Beaufour-Ipsen,Biokeys Pharmaceuticals, Biomedicines, Biomira, Bionomics, Biosyntech, BioTie Therapies, BioVex, Bioxel, Boehringer Ingelheim, Boston Life Sciences, Bristol-Myers Squibb, British Biotech, CancerVax,Celgene,Cell Genesys, Cell Pathways, Cell Therapeutics, Cellegy Pharmaceuticals, CEL-SCI, Centacor, ChemGenex Therapeutics, Chiron,Coley Pharmaceuticals, Conforma Therapeutics, Copernicus, Corixa, Crucell, Cyclacel, Cytel, Cytochroma, Cytokinetics, Dainippon Pharmaceutical Co, Dekk- Tec, Dendreon, Eisai Co, Elan, Eli Lilly & Co, Enact Pharma, Endorecherche, EntreMed, Epimmune, Exegenics, ExonHit Therapeutics, FibroGen, Galderma Research & Development, GD Searle & Co, Gemin X Biotechnologies, Genaera, GeneMax, Genentech, Generex, Genta, Genzyme, GlaxoSmithKline, GlycoGenesys, Helix Biopharma, Hormos Medical, Hybridon, ICN Pharmaceuticals, Idun Pharmaceuticals, ILEX Oncology, ImClone Systems, Immunex, ImmunoGen, Immunomedics, Immusol, Incyte, INEX Pharmaceuticals, Insmed, Introgen Therapeutics, Isis Pharmaceuticals, Janssen Pharmaceutica, Johnson&Johnson, Karo Bio, Keryx Biopharmaceuticals, Kirin Brewery Co, Kosan Biosciences, Kyowa Hakko, Lane Labs, Leo Pharmaceutical Products, Ligand Pharmaceuticals, Lorus Therapeutics, Matrix Pharmaceutical, Maxia Pharmaceuticals, Maxim Pharmaceuticals, McNeil Pharmaceuticals, Medarex, MediGene, MediQuest Therapeutics, Meditech Research, Merck, MGI Pharma,Millenium, Miravant Medical Technologies, ML Laboratories, Molecular Engines Laboratories, Myriad Genetics, NEMOD Immuntherapie, NeoPharm , NeoRx, Neurocrine Biosciences, NeXstar Pharmaceuticals, Nippon Roche, Novartis, Novo Nordisk, Novogen, Oncolytics Biotech, Ontogen, OSI, Oxford BioMedica, OXiGENE, Paracelsian, Peregrine Pharmaceuticals, Pfizer, Pharmacia, Pharmacyclics, PharmaMar, Pharmexa, Pharmos, Pierre Fabre, ProIX, Prolifix, Protein Design Labs, Protheon, QLT, Regulon, Ribozyme Pharmaceuticals, Roche, Sanofi-Synthelabo, Schering, Schering-Plough, SciClone, Serono, Shire Pharmaceuticals, Sigma-tau Research, SR Pharma, Structural Bioinformatics, SUGEN, SuperGen, Taiho Pharmaceutical Co, Takeda, Targeted Genetics, Telik, Theratechnologies, Therion Biologics, Titan Pharmaceuticals, Transgene, Tularik, Vaccinex, Vaxin Pharmaceuticals, Vertex Pharmaceuticals, Vion Pharmaceuticals, Viragen, Viventia Biotech, Wyeth, Xcyte Therapies, Xenova Group, XOMA, Yamanouchi Pharmaceutical, YM Biosciences, Zenyaku Kogyo Co, Zonagen. TABLE OF CONTENTS Contents Executive Summary Introduction Information Analyses List of Tables Table 1. Emerging cancer therapies Table 2. Key trends that will drive the oncology market in the near future Table 3. COMPANIES: Summarizing the Field of Breast Cancer R&D in Relation to Company Table 4. STAGE: Summarizing the Field of Breast Cancer R&D in Relation to Stage Table 5. EFFECT: Summarizing the Field of Breast Cancer R&D in Relation to Effect Table 6. THERAPY: Summarizing the Field of Breast Cancer R&D in Relation to Therapy Table 7. MECHANISM: Summarizing the Field of Breast Cancer R&D in Relation to Mechanism Table 8. EARLY/LATE STAGE: Summarizing the Field of Breast Cancer R&D in Relation to Early (Preclinical to Phase I/II) and Late (Phase II/III to Phase III) Stage Table 9. Summary of the Number of Projects for each Company in Relation to Stage Table 10. Summary of the Number of Projects for each Company in Relation to Therapeutic Effect Table 11. Summary of the Number of Projects for each Company in Relation to Therapy Given Table 12. Summary of the Number of Projects for each Therapeutic Effect in Relation to Stage Table 13. Summary of the Number of Projects for each Therapy Given in Relation to Stage Table 14. Summary of the Number of Projects for each Mechanism in Relation to Stage List of Pictures Picture 1. Expected growth of global oncology market Picture 2. Number of Antiangiogenesis Projects in Relation to Stage Picture 3. Number of Apoptosis Projects in Relation to Stage Picture 4. Number of Cytotoxic Projects in Relation to Stage Picture 5. Number of Growth Inhibition Projects in Relation to Stage Picture 6. Number of Hormonal Therapy Projects in Relation to Stage Picture 7. Number of Immunotherapy Projects in Relation to Stage Picture 8. Number of Preclinical Projects in Relation to Effect Picture 9. Number of Phase I Projects in Relation to Effect Picture 10. Number of Phase I/II Projects in Relation to Effect Picture 11. Number of Phase II Projects in Relation to Effect Picture 12. Number of Phase III Projects in Relation to Effect Picture 13. Number of Anti- idiotype Antibody Projects in Relation to Stage Picture 14. Number of Antisense Projects in Relation to Stage Picture 15. Number of Biological Projects in Relation to Stage Picture 16. Number of Cell Therapy Projects in Relation to Stage Picture 17. Number of Gene Therapy Projects in Relation to Stage Picture 18. Number of Monoclonal Antibody Projects in Relation to Stage Picture 19. Number of Small Molecular Drug Projects in Relation to Stage Picture 20. Number of Preclinical Projects in Relation to Therapy Given Picture 21. Number of Phase I Projects in Relation to Therapy Given Picture 22. Number of Phase I/II Projects in Relation to Therapy Given Picture 23. Number of Phase II Projects in Relation to Therapy Given Picture 24. Number of Phase III Projects in Relation to Therapy Given Picture 25. Number of Cell-cycle Inhibitor Projects in Relation to Effect Picture 26. Number of Cytokine Induction Projects in Relation to Effect Picture 27. Number of DNA Targeting Projects in Relation to Effect Picture 28. Number of GNRH/LHRH Antagonist Projects in Relation to Effect Picture 29. Number of Radiotherapy Projects in Relation to Effect Picture 30. Number of Retinoid Projects in Relation to Effect Picture 31. Number of Tumor Antigen Projects in Relation to Effect Picture 32. Number of Antiangiogenesis Projects in Relation to Mechanism Picture 33. Number of Apoptosis Projects in Relation to Mechanism Picture 34. Number of Cytotoxic Projects in Relation to Mechanism Picture 35. Number of Growth Inhibition Projects in Relation to Mechanism Picture 36. Number of Hormonal Therapy Projects in Relation to Mechanism Picture 37. Number of Immunotherapy Projects in Relation to Mechanism Picture 38. Number of Bcl-2 Projects in Relation to Therapy Given Picture 39. Number of Cell-Cycle Inhibitor Projects in Relation to Therapy Given Picture 40. Number of Cytokine Induction Projects in Relation to Therapy Given Picture 41. Number of DNA Targeting Projects in Relation to Therapy Given Picture 42. Number of EGF Antagonist Projects in Relation to Therapy Given Picture 43. Number of Estrogen Modulator Projects in Relation to Therapy Given Picture 43. Number of Estrogen Modulator Projects in Relation to Therapy Given Picture 44. Number of GNRH/LHRH Agonist Projects in Relation to Therapy Given Picture 45. Number of GNRH/LHRH Antagonist Projects in Relation to Therapy Given Picture 46. Number of Multi Drug Resistance Projects in Relation to Therapy Given Picture 47. Number of Oncolytic Virus Projects in Relation to Therapy Given Picture 48. Number of Polyamine Synthesis Projects in Relation to Therapy Given Picture 50. Number of Radiotherapy Projects in Relation to Therapy Given Picture 51. Number of Tumor Antigen Projects in Relation to Therapy Given Picture 52. Number of VEGF Antagonist Projects in Relation to Therapy Given Picture 53. Number of Antisense Projects in Relation to Mechanism Picture 54. Number of Biological Projects in Relation to Mechanism Picture 55. Number of Gene Therapy Projects in Relation to Mechanism Picture 56. Number of Monoclonal Antibody Projects in Relation to Mechanism Picture 57. Number of Small Molecular Drug Projects in Relation to Mechanism Picture 58. Number of Antisense Projects in Relation to Effect Picture 59. Number of Biological Projects in Relation to Effect Picture 60. Number of Cell Therapy Projects in Relation to Effect Picture 61. Number of Gene Therapy Projects in Relation to Effect Picture 62. Number of Monoclonal Antibody Projects in Relation to Effect Picture 63. Number of Small Molecular Drug Projects in Relation to Effect Picture 64. Number of Antiangiogenesis Projects in Relation to Therapy Given Picture 65. Number of Apoptosis Projects in Relation to Therapy Given Picture 66. Number of Cytotoxic Projects in Relation to Therapy Given Picture 67. Number of Growth Inhibition Projects in Relation to Therapy Given Picture 68. Number of Hormonal Therapy Projects in Relation to Therapy Given Picture 69. Number of Immunotherapy Projects in Relation to Therapy Given Picture 70. Number of Vascular Targeting Projects in Relation to Therapy Given Picture 71. Clinical Pipeline Trends in Relation to Effect Picture 72. Clinical Pipeline Trends in Relation to Therapy Given Picture 73. Clinical Pipeline Trends in Relation to Mechanism Picture 74. Antiangiogenesis Clinical Pipeline Trends in Relation to Mechanism Picture 75. Antiangiogenesis Clinical Pipeline Trends in Relation to Therapy Given Picture 76. Apoptosis Clinical Pipeline Trends in Relation to Mechanism Picture 77. Apoptosis Clinical Pipeline Trends in Relation to Therapy Given Picture 78. Cytotoxic Clinical Pipeline Trends in Relation to Mechanism Picture 79. Cytotoxic Clinical Pipeline Trends in Relation to Therapy Given Picture 80. Growth Inhibition Clinical Pipeline Trends in Relation to Mechanism Picture 81. Growth Inhibition Clinical Pipeline Trends in Relation to Therapy Given Picture 82. Hormonal Therapy Clinical Pipeline Trends in Relation to Mechanism. Picture 83. Hormonal Therapy Clinical Pipeline Trends in Relation to Therapy Given Picture 84. Immunotherapy Clinical Pipeline Trends in Relation to Mechanism Picture 85. Immunotherapy Clinical Pipeline Trends in Relation to Therapy Given Picture 86. Anti- idiotypic Antibody Clinical Pipeline Trends in Relation to Effect Picture 87. Anti- idiotypic Antibody Clinical Pipeline Trends in Relation to Mechanism Picture 88. Antisense Clinical Pipeline Trends in Relation to Effect Picture 89. Antisense Clinical Pipeline Trends in Relation to Mechanism Picture 90. Biological Drugs Clinical Pipeline Trends in Relation to Effect Picture 91. Biological Drugs Clinical Pipeline Trends in Relation to Mechanism Picture 92. Cell Therapy Clinical Pipeline Trends in Relation to Effect Picture 93. Cell Therapy Clinical Pipeline Trends in Relation to Mechanism Picture 94. Gene Therapy Clinical Pipeline Trends in Relation to Effect Picture 95. Gene Therapy Clinical Pipeline Trends in Relation to Mechanism Picture 96. Monoclonal Antibody Clinical Pipeline Trends in Relation to Effect Picture 97. Monoclonal Antibody Clinical Pipeline Trends in Relation to Mechanism Picture 98. Small Molecular Drugs Clinical Pipeline Trends in Relation to Effect Picture 99. Small Molecular Drugs Clinical Pipeline Trends in Relation to Mechanism Picture 100. Protein Kinase Inhibitor Clinical Pipeline Trends in Relation to Effect Picture 101. Protein Kinase Inhibitor Clinical Pipeline Trends in Relation to Therapy Given Picture 102. Protein Kinase Inhibitor Clinical Pipeline Trends in Relation to Mechanism Picture 103. Tumor Antigen Clinical Pipeline Trends in Relation to Therapy Given Picture 104. Pipeline Trends in Relation to Effect Picture 105. Pipeline Trends in Relation to Therapy Given Picture 106. Pipeline Trends in Relation to Mechanism Discovery R&D

No additional author information available for this product